Organogenesis Holdings Inc (OQ:ORGO)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 85 Dan Rd
CANTON MA 02021-2810
Tel: N/A
Website: https://investors.organogenesis.com
IR: See website
<
Key People
Gary S. Gillheeney
President, Chief Executive Officer, Director
Henry Hagopian
Interim Chief Financial Officer, Vice President - Finance, Treasurer
Patrick Bilbo
Chief Operating Officer
Lori Freedman
Vice President, General Counsel
Antonio S. Montecalvo
Vice President - Health Policy and Contracting
Brian Grow
Chief Commercial Officer
Business Overview
Organogenesis Holdings Inc., formerly Avista Healthcare Public Acquisition Corp, is a regenerative medicine company. The Company focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. It also provides integrated healing solutions that substantially improve medical outcomes. The Company's advanced wound care and surgical & sports medicine products include PuraPly, Antimicrobial (PuraPlyAM), PuraPly, Affinity, NuShield, Apligraf and Dermagraft. The Company is offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. The Company's comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
Financial Overview
For the nine months ended 30 September 2020,Organogenesis Holdings Inc revenues increased 24% to$231.5M. Net loss applicable to common stockholdersdecreased 99% to $545K. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Lower net loss reflects Losson the extinguishment of debt decrease from $1.9M (expense)to $0K.
Employees: 835 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $713.81M as of Sep 30, 2020
Annual revenue (TTM): $306.14M as of Sep 30, 2020
EBITDA (TTM): $11.51M as of Sep 30, 2020
Net annual income (TTM): -$4.94M as of Sep 30, 2020
Free cash flow (TTM): -$41.59M as of Sep 30, 2020
Net Debt Last Fiscal Year: $78.22M as of Sep 30, 2020
Shares outstanding: 107,785,526 as of Nov 1, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.